The global anticoagulants market was valued at US$ 29,150.7 Mn in 2021 and expected to grow at compound annual growth rate (CAGR) of 6.0% during the forecast period from 2025 to 2033. Anticoagulants are prescribed to patients who are at higher risk of clot formation in the blood and reduce the risk of serious conditions such as strokes and heart attacks. Anticoagulants are also given to treat pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation and other cardiovascular diseases. Thus, increasing prevalence of cardiovascular diseases, especially DVT, atrial fibrillation and peripheral artery diseases is a major growth factor assisting the market. Launch of several novel oral anticoagulants (NOACs) with improved properties in the last decade has completely changed the market scenario over the years. Warfarin a vitamin K antagonists was the most preferred anticoagulants earlier as it was efficient in inhibiting the vitamin K recycling. However, use of warfarin had certain limitations such as continuous monitoring of international normalized ratio (INR) i.e. drug levels and drug-food & drug-drug interactions, acting as the drawbacks for the market.

NOACs are also referred as non-vitamin K antagonist oral anticoagulants, consisting for coagulation factors Xa inhibitors, factor IIa inhibitors and direct thrombin inhibitors which has faster onset of drug and lowered side effects compared to other drugs. The currently marketed NOACs include babigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana/Savaysa) and betrixaban (Bevyxxa). Xarelto by Bayer/ Janssen Pharmaceuticals and Eliquis by Pfizer/ Bristol-Myers Squibb are the most prescribed NOACs globally owing to impressing efficacy rate in the trials, lower side-effects such as uncontrollable bleeding and the ability of the drugs to treat multiple indications, provide an upper hand in the market. Bevyxxa by Portola Pharmaceuticals was the latest addition in the market, getting U.S. Food and Drug Administration (FDA) approval in June 2017 and launched in January 2018 for prophylaxis of venous thromboembolism (VTE). This will further drive the market for anticoagulants market.

"Novel Oral Anticoagulants Will Drive the Anticoagulants Market During the Forecast Period"  

In 2021, NOACs held the largest share of more than 50% of the overall anticoagulants market. The segment is projected to exhibit fastest growth rate during the forecast period as NOACs provides higher advantage over vitamin K antagonist in terms of safety, lower side effects such as bleeding episodes, decreased need for continuous dosage monitoring and availability of anticoagulant reversal agents. Higher prices of NOACs as compared to other drug segment also leads to the growth of the market.

Market is studied in order to understand the current dynamics and future trends in the global anticoagulants market.  The key players currently engaged in anticoagulants market include Bayer AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company Limited, and Portola Pharmaceuticals, Inc. among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anticoagulants market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Anticoagulants market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Anticoagulants market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Anticoagulants market?
• Which is the largest regional market for Anticoagulants market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Anticoagulants market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Anticoagulants market worldwide?